AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
This announcement contains inside information 24 August 2016 07:00 ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases willextend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. (Pfizer) to sell the commercialisation and development rights to its late-stage